Free Trial

Amarin (AMRN) Stock Forecast & Price Target

$0.78
-0.01 (-1.26%)
(As of 07/19/2024 ET)

Amarin - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 4 Wall Street analysts who have issued ratings for Amarin in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 4 analysts, 2 have given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for AMRN.

Consensus Price Target

$1.00
27.42% Upside
High Forecast$1.00
Average Forecast$1.00
Low Forecast$1.00

According to the 4 analysts' twelve-month price targets for Amarin, the average price target is $1.00. The highest price target for AMRN is $1.00, while the lowest price target for AMRN is $1.00. The average price target represents a forecasted upside of 27.42% from the current price of $0.78.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Reduce
Reduce
Reduce
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$1.00$1.08$1.08$1.81
Forecasted Upside27.42% Upside5.99% Upside5.99% Upside50.15% Upside
Get Amarin Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

AMRN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AMRN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Amarin Stock vs. The Competition

TypeAmarinMedical CompaniesS&P 500
Consensus Rating Score
1.75
2.72
2.51
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside27.42% Upside3,282.90% Upside10.04% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/18/2024Cantor Fitzgerald
3 of 5 stars
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
11/20/2023JPMorgan Chase & Co.
3 of 5 stars
 Reiterated RatingUnderweight
10/25/2023Jefferies Financial Group
2 of 5 stars
 DowngradeBuy ➝ Hold$3.00 ➝ $1.00+31.53%
7/20/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSell$1.50 ➝ $1.00-7.41%
7/19/2023Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$2.00 ➝ $1.25-12.59%
10/19/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Ruiz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetMarket Perform$3.00 ➝ $2.00+70.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:23 PM ET.

AMRN Forecast - Frequently Asked Questions

What is Amarin's forecast for 2024?

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Amarin is $1.00, with a high forecast of $1.00 and a low forecast of $1.00.

Should I buy or sell Amarin stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.

Does Amarin's stock price have much upside?

According to analysts, Amarin's stock has a predicted upside of 8.68% based on their 12-month stock forecasts.

What analysts cover Amarin?

Amarin has been rated by research analysts at Cantor Fitzgerald in the past 90 days.

Do Wall Street analysts like Amarin more than its competitors?

Analysts like Amarin less than other "medical" companies. The consensus rating for Amarin is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMRN compares to other companies.


This page (NASDAQ:AMRN) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners